Science
Chinese research team identifies a new mechanism of ovarian aging Blocking cGAS-STING signaling improves reproductive function in aged mice

A study has found that leakage of mitochondrial DNA (mtDNA) from oocytes drives ovarian aging. Inhibiting this signaling pathway was found to restore reproductive function in aged mice.
A research team led by Yang Qingling of Zhengzhou University in China published the findings Aug. 28 (local time) in the journal Nature Aging.
The ovaries age earlier than other organs. Follicle numbers decline, oocyte quality deteriorates and chronic inflammation increases. However, the specific mechanisms that cause ovarian aging have not been clearly established.
The research team focused on the fact that oocytes are the largest cells in the body and are rich in mitochondria. Oocytes rely on mitochondrial health to support fertilization and early embryonic development, but their limited capacity to repair mtDNA makes them vulnerable to age-related functional decline.
The study found that in aged oocytes, mtDNA leaked into the cytoplasm and activated an innate immune signaling pathway called cGAS-STING. This pathway normally detects external threats such as viruses.
The signaling molecule cGAMP produced in oocytes passed through intercellular channels to nearby granulosa cells, triggering an inflammatory response. The research team confirmed that mtDNA leakage, inflammation and impaired ovarian function were reproduced in a mouse model in which the Tfam gene was specifically deleted in oocytes.
Conversely, deleting the Cgas gene in these mice or blocking STING signaling with the drug H-151 improved ovarian dysfunction. The research team said that mtDNA leakage from oocytes is a direct cause of ovarian aging and that cGAS-STING signaling could be a therapeutic target.

Biobook Team
biobookmedia@biobook.co.kr
Roche and Zealand’s Amylin Drug Shows Limited Glucose-Lowering Effect, Potentially Narrowing Its Role to Maintenance Therapy

HLB Makes Fourth Attempt to Win Liver Cancer Drug Approval; Manufacturing Inspection Risks Remain

HLB Submits FDA Resubmission for Liver Cancer First-Line Treatment

Nature Cell Wins First-Instance Ruling on Jointstem … “Order for Reconsideration, Not Approval”

Biohub’s $2.4 Billion ‘Virtual Cell’ Project Gives Big Tech 1-Year Exclusive Data Access

Korean Biotechs Target DMOADs for Cartilage Regeneration in Race for Global First
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash